BioSpace News Archive

Autolus is currently working on advancing obecabtagene autoleucel, its CD19 CAR T cell investigational therapy product candidate, in addition to other applications of obe-cel in B-cell malignancies.

While some get the jab faithfully each flu season, about half of the American population declines, likely over doubts of the vaccine’s effectiveness and necessity.

According to the report, the global cell line authentication and characterization tests market was valued over US$ 308 Mn in 2020 and is projected to expand at a CAGR of 8.4% from 2021 to 2031.

Royal Philips, a global leader in health technology, announced that it has signed an agreement to acquire Cardiologs, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence and cloud technology.

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it has fully enrolled the metastatic uveal melanoma expansion cohort of the DIONE-01 study evaluating iOnctura’s lead compound, the selective PI3Kδ inhibitor IOA-244.

Masimo announced the findings of a prospective study published in Frontiers in Aging Neuroscience in which Dr. Shuyi Yang and colleagues at Capital Medical University in Beijing investigated whether Masimo Root® with a multimodal brain monitoring algorithm to manage anesthesia during spinal surgery could improve postoperative cognitive function.

Hansa Biopharma AB “Hansa”, the pioneer in enzyme technology for rare immunological conditions, announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of American Depositary Shares in the United States representing Hansa’s ordinary shares and listing of ADSs on the Nasdaq Stock Market.

Moberg Pharma AB has entered into a collaboration with Allderma AB for the launch of MOB-015 in Sweden, Norway and Denmark.

Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved conditions, announced the U.S. Food and Drug Administration approval of EPRONTIA™ oral solution, 25 mg/mL.

Matinas BioPharma Holdings, Inc. today reported financial results for the third quarter ended September 30, 2021, along with a corporate update.